58.
[1]. A Pezeshk, et al. Drug-metal interactions: spectroscopic studies of copper hydantoin complexes. J Inorg Biochem. 1991 Jun;4(4):67-7.
[]. H Fujioka, et al. Biopharmaceutical studies on hydantoin derivatives. V. Pharmacokinetics and pharmacodynamics of 5,5-diphenylhydantoin and 1-benzenesulfonyl-5,5-diphenylhydantoin. J Pharmacobiodyn. 1986 Mar;9(3):303-14.
[3]. Hisashi Suzuki, et al. Active-site characteristics of CYPC19 and CYPC9 probed with hydantoin and barbiturate inhibitors. Arch Biochem Biophys. 004 Sep 1;49(1):1-15.
[4]. I H Hall, et al. A comparison of the S(+) and R(-) enantiomers of 5-ethyl-5-phenylhydantoin as hypolipidemic agents in rodents. Biomed Biochim Acta. 1987;46(7):63-34.
[5]. R A Lubet, et al. A markedly diminished pleiotropic response to phenobarbital and structurally-related xenobiotics in Zucker rats in comparison with F344/NCr or DA rats. Biochem Pharmacol. 199 Mar 3;43(5):1079-87.
H30-H315-H319-H335
P61-P64-P70-P71-P80-P30+P35-P304+P340-P330-P36+P364-P405-P501